Dacia Manifesto concept sets out budget brand’s vision of rugged, sustianable and affordable future
Among its wilder concept features are cartoonish airless tyres, a hose-down interior and seat covers that can be whipped off and turned into sleeping bags. There’s also a removable rear-mounted battery that can be used as a power source and single headlight that can be removed and used as a torch - like Skoda’s removable boot light on steroids.
Another feature of the Manifesto that is likely to find its way into regular road cars is its use of sustainable materials. Inside, natural materials such as cork are used for the dashboard, and less sustainable features such as chrome trim has been removed - just like its current range. The greener materials extend to the car’s body panels which are made from a new recycled plastic dubbed Starkle and which Dacia says will be used for visible external components in future models.
That’s reflected in the Manifesto’s simple smartphone dock, which is similar to the system already found in lower-spec Dacias.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Farmer, 77, beaten to death by kangaroo had raised it since it was a joeyAn alpaca farmer has been killed by a kangaroo he had raised since birth.
Consulte Mais informação »
Meghan Markle dress detail sparks 'wild' fan theory about recording deviceThe Duchess and her husband Prince Harry have been seen at numerous royal events this week, and a small detail spotted by fans has forced a source close to the couple to speak out
Consulte Mais informação »
Highly-Contagious Rabbit Disease Detected in ConnecticutThe Connecticut Department of Agriculture has confirmed cases of Rabbit Hemorrhagic Disease Virus Type 2 (RHDV2) in a group of rabbits at a home in Hartford County. The highly contagious disease can be fatal to wild and domestic rabbits, according to the Department of Agriculture. It cannot be transmitted from animals to humans. The agency received a report of the…
Consulte Mais informação »
Farmer beaten to death by pet kangaroo had raised animal since it was a babyAN ELDERLY alpaca farmer who kept a wild kangaroo as a pet has died after the beast savaged him at his Western Australia home. Peter Eades, 77, was discovered by a family member after being attacke…
Consulte Mais informação »
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia | Journal of Clinical OncologyPURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n=56 FLT3mut); 64% (n=36 of 56) of FLT3mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n=49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (| 10−2) was achieved in 60% of evaluable mCRc patients (n=15 of 25). The median overall survival for FLT3mut patients was
Consulte Mais informação »